Humacyte, Inc. (HUMA) Form SCHEDULE 13D/A — Aug 18, 2026
Fresenius Medical Care Holdings and its parent Fresenius Medical Care AG disclosed in Amendment No. 11 to their Schedule 13D that they sold 4,709,500 Humacyte (HUMA) shares between August 10 and August 17, 2026 for aggregate proceeds of roughly $2.78 million, cutting their stake to 13,603,235 shares, or approximately 4.9% of Humacyte's 277,798,105 outstanding voting shares. The sales were executed on Nasdaq under a Rule 10b5-1 plan established July 10, 2026, with Citigroup Global Markets acting as agent. Weighted average prices slid from $0.7249 per share on August 10 to $0.5547 per share on August 17, meaning HUMA traded well below $1 throughout the entire sale window.
Key figures
- Shares Outstanding
- 277798105
- Plan type
- Rule 10b5-1 plan established July 10, 2026
- Plan agent
- Citigroup Global Markets Inc.
- Shares owned
- 13603235
- Percent owned
- 4.9%
- Amendment number
- 11
- Original 13d filed
- 2021-09-02
- Weighted avg sale prices
- $0.7249 (Aug 10) declining to $0.5547 (Aug 17)
- Ceased 5pct ownership date
- 2026-08-17
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.